{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:32Z","timestamp":1791927932096,"version":"4.3.4"},"reference-count":60,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods\u2014centralized, manual, and complex\u2014are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to compare CAR-T therapy produced by the AIDPATH platform to both ciltacabtagene autoleucel (cilta-cel) and standard of care (SoC) for patients with triple-class refractory multiple myeloma (MM) over a 40-year time horizon from the hospital perspective in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for cilta-cel, real-world data for SoC, and estimated parameters for AIDPATH due to the developmental status of the platform. The primary outcome was the incremental cost-effectiveness ratio; secondary outcomes included sensitivity and scenario analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On the basis of the model used in this analysis, AIDPATH was dominant compared to both cilta-cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed that the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein times for AIDPATH, further supported its cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to assess the cost-effectiveness of a CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both cilta-cel and SoC, making it a promising option for future implementation. Although further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/92253","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:40:10Z","timestamp":1778701210000},"page":"e92253","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital\u2013Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4760-412X","authenticated-orcid":false,"given":"Iris W A","family":"Boot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5522-9327","authenticated-orcid":false,"given":"Anna Louisa","family":"Weltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-7276","authenticated-orcid":false,"given":"Ysanne","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-4671","authenticated-orcid":false,"given":"Hubertus J M","family":"Vrijhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.913287"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.2639"},{"key":"ref5","unstructured":"DiemerFSFarmacotherapeutisch rapport ciltacabtagene autoleucel (Carvykti\u00ae) bij recidiverend en refractair multipel myeloom na ten minste drie eerdere behandelingen [Article in Dutch]Zorginstituut Nederland20222026-04-23https:\/\/tinyurl.com\/mv33y36s"},{"key":"ref6","unstructured":"Ciltacabtagene Autoleucel (CARVYKTI\u00ae) [Article in German]Gemeinsamer Bundesausschuss20232026-04-23https:\/\/www.g-ba.de\/downloads\/92-975-6400\/2023_02_14_Janssen_Dossier_Ciltacel_rrMM_Modul3.pdf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22669"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235996"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33156"},{"key":"ref12","unstructured":"DRG-Entgelttarif 2022 f\u00fcr die Klinikum W\u00fcrzburg Mitte gGmbH [Article in German]Klinikum W\u00fcrzburg Mitte20222026-04-23https:\/\/www.kwm-klinikum.de\/assets\/downloads\/KWM%20DRG%20Entgelt%2001.8.2022.pdf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00228-5"},{"key":"ref14","unstructured":"Tisagenlecleucel (Kymriah\u00ae)Gemeinsamer Bundesausschuss20222026-04-23https:\/\/www.g-ba.de\/downloads\/92-975-5819\/2022_05_25_Modul3A_Tisagenlecleucel.pdf"},{"key":"ref15","author":"Latimer, NR","year":"2013","journal-title":"Survival Analysis For Economic Evaluations Alongside Clinical Trials - Extrapolation with Patient-Level Data"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101745"},{"key":"ref17","unstructured":"JacksonCThomHVGDifferent models for different purposes: focused model comparison in RMRC Biostatistics Unit2026-09-23https:\/\/r-mirror.zim.uni-due.de\/web\/packages\/fic\/vignettes\/fic.pdf"},{"key":"ref18","unstructured":"Medicinal Products Act in the version published on 12 December 2005 (Federal Law Gazette [BGBl.]) Part I p. 3394, last amended by Article 11 of the Act of 6 May 2019 (Federal Law Gazette I p. 646)LawEuro20212026-09-23https:\/\/laweuro.com\/?p=14930"},{"key":"ref19","unstructured":"HeckenJustification to the resolution of the Federal Joint Committee (G-BA) on an amendment of the pharmaceuticals directive (AM-RL): Annex XII \u2013 benefit assessment of medicinal products with new active ingredients according to section 35a SGB V polatuzumab vedotin (diffuse large B-Cell lymphoma, combination with bendamustine and rituximab)Gemeinsamer Bundesausschuss20202026-09-23https:\/\/www.g-ba.de\/downloads\/40-1465-6796\/2020-08-20_AM-RL-XII_Polatuzumab-Vedotin_D-507_TrG_EN.pdf"},{"key":"ref20","unstructured":"Justification to the resolution of the Federal Joint Committee (G-BA) on an amendment of the pharmaceuticals directive (AM-RL): Annex XII \u2013 benefit assessment of medicinal products with new active ingredients according to section 35a SGB V daratumumab (new therapeutic indication: multiple myeloma, newly diagnosed, patients eligible for autologous stem cell transplant, combination with bortezomib, thalidomide, and dexamethasone)Gemeinsamer Bundesausschuss20202026-09-23https:\/\/www.g-ba.de\/downloads\/40-1465-6794\/2020-08-20_AM-RL-XII_Daratumumab_D-522_TrG_EN.pdf"},{"key":"ref21","year":"2018","journal-title":"Daratumumab (Darzalex\uf8e8) {German]"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705210"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2011.26.4.403"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"ref27","unstructured":"Multiple myeloma [Article in Dutch]Nederlandse Vereniging voor Hematologie20242026-09-23https:\/\/publicatie.hematologienederland.nl\/richtlijnen\/multipel-myeloom\/"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170118"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2174\/1871529X21666210412113017"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00357-4"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14821"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0616"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.5045\/br.2016.51.3.193"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605417"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.959589"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0757-y"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3338.3338"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268822001182"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/2197-425X-3-S1-A50"},{"key":"ref42","unstructured":"The old GHO Minerva interface and GHO Athena API are retiredWorld Health Organization2026-04-23https:\/\/www.who.int\/data\/gho\/legacy?lang=en"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.18609\/cgti.2020.058"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1612248"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.09.002"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00063-024-01230-z"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1613836"},{"key":"ref48","unstructured":"GENESIS OnlineStatistisches Bundesamt (Destatis)2026-04-23https:\/\/www-genesis.destatis.de\/datenbank\/online\/"},{"key":"ref49","unstructured":"General methodsIQWiG2026-04-23https:\/\/www.iqwig.de\/en\/methods\/methods-paper\/"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.09.013"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-018-0154-3"},{"key":"ref53","unstructured":"Incremental cost-effectiveness ratio (ICER)York Health Economics Consortium2016102025-04-23https:\/\/yhec.co.uk\/glossary\/incremental-cost-effectiveness-ratio-icer\/"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305189"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2022.1026474"},{"key":"ref56","unstructured":"Your research: subject to the WMO or not?Central Committee on Research Involving Human Subjects2026-04-23https:\/\/english.ccmo.nl\/investigators\/legal-framework-for-medical-scientific-research\/your-research-is-it-subject-to-the-wmo-or-not"},{"key":"ref57","unstructured":"Obtaining ethical approvalKonsortSWD2026-04-23https:\/\/www.konsortswd.de\/en\/topics\/best-practices-research-ethics\/researchers\/ethical-approval\/"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.01.010"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2024.100868"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462325100147"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e92253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:55:09Z","timestamp":1791924909000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e92253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2196\/92253","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.92253","asserted-by":"object"}]},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}